Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Cash from Operations (2016 - 2025)

Traws Pharma (TRAW) has disclosed Cash from Operations for 14 consecutive years, with 4011000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations rose 65.05% to 4011000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 19467000.0, a 35.5% increase, with the full-year FY2024 number at 29792000.0, down 66.14% from a year prior.
  • Cash from Operations was 4011000.0 for Q3 2025 at Traws Pharma, up from 5979000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 3884000.0 in Q4 2022 to a low of 11476000.0 in Q3 2024.
  • A 5-year average of 5206947.37 and a median of 4424000.0 in 2024 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: tumbled 156.79% in 2024, then soared 65.05% in 2025.
  • Traws Pharma's Cash from Operations stood at 4265000.0 in 2021, then rose by 8.93% to 3884000.0 in 2022, then fell by 14.06% to 4430000.0 in 2023, then grew by 8.8% to 4040000.0 in 2024, then rose by 0.72% to 4011000.0 in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Cash from Operations are 4011000.0 (Q3 2025), 5979000.0 (Q2 2025), and 5437000.0 (Q1 2025).